Connect with us

HEALTH

LifeStance Health Group (NASDAQ:LFST) Shares Down 4.6% on Analyst Downgrade

Published

on

LifeStance Health Group logo

[ad_1]

LifeStance Health Group, Inc. (NASDAQ:LFST – Get Rating) fell 4.6% in midday trading on Tuesday after Goldman Sachs Group lowered its price target on the stock from $9.00 to 8 $.00. Goldman Sachs Group currently has a neutral rating on the stock. LifeStance Health Group traded as low as $5.81 and last traded at $5.84. Around 19,884 shares were traded at midday, down 97% from the average daily volume of 714,671 shares. The stock previously closed at $6.12.

A number of other analysts have also recently weighed in on the stock. Jefferies Financial Group restated a “buy” rating and issued a price target of $7.25 on LifeStance Health Group shares in a Monday, Nov. 7, report. Cowen lowered his price target on LifeStance Health Group shares from $10.00 to $8.00 and set an “outperform” rating for the company in a research report on Monday. Finally, Cowen lowered his price target on LifeStance Health Group shares from $10.00 to $8.00 and set an “outperform” rating for the company in a research report on Monday. Three research analysts gave the stock a hold rating and three gave the stock a buy rating. According to data from MarketBeat.com, LifeStance Health Group has a consensus rating of “Moderate Buy” and an average price target of $8.54.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, insider Warren Gouk sold 15,106 shares of the company in a trade that took place on Monday, November 7. The shares were sold at an average price of $7.20, for a total transaction of $108,763.20. Following the transaction, the insider now owns 5,967,991 shares of the company, valued at approximately $42,969,535.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. In other LifeStance Health Group news, insider Warren Gouk sold 15,106 shares of the company in a trade that took place on Monday, November 7. The shares were sold at an average price of $7.20, for a total transaction of $108,763.20. Following the transaction, the insider now owns 5,967,991 shares of the company, valued at approximately $42,969,535.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, insider Kevin Michael Mullins sold 82,520 shares of the company in a trade that took place on Friday, September 30. The shares were sold at an average price of $7.03, for a total transaction of $580,115.60. Following the transaction, the insider now owns 5,584,540 shares of the company, valued at approximately $39,259,316.20. The disclosure of this sale can be found here. Insiders sold 276,503 shares of the company valued at $2,075,888 in the past 90 days. Insiders hold 16.59% of the shares of the company.

LifeStance Health Group Institutional Trading

A number of hedge funds and other institutional investors have recently changed their positions in LFST. Vanguard Group Inc. increased its holdings in LifeStance Health Group by 79.6% in the first quarter. Vanguard Group Inc. now owns 6,202,930 shares of the company worth $62,711,000 after purchasing an additional 2,749,277 shares in the last quarter. Stockbridge Partners LLC purchased a new stock position in LifeStance Health Group in the first quarter for a value of approximately $53,529,000. BlackRock Inc. increased its position in LifeStance Health Group by 21.7% during the third quarter. BlackRock Inc. now owns 5,146,718 shares of the company worth $34,073,000 after purchasing an additional 915,997 shares in the last quarter. Principal Financial Group Inc. increased its position in LifeStance Health Group by 34.8% during the second quarter. Principal Financial Group Inc. now owns 3,367,625 shares of the company worth $18,724,000 after purchasing an additional 868,946 shares in the last quarter. Finally, O Brien Wealth Partners LLC acquired a new stake in LifeStance Health Group during the second quarter valued at approximately $6,503,000. Institutional investors and hedge funds hold 78.05% of the company’s shares.

Healthcare group LifeStance trades down 4.7%

The company has a market capitalization of $2.19 billion, a price-earnings ratio of -7.72 and a beta of 0.89. The company’s 50-day simple moving average is $7.59 and its two-hundred-day simple moving average is $6.94. The company has a quick ratio of 2.25, a current ratio of 2.25 and a leverage ratio of 0.14.

LifeStance Health Group Company Profile

(Get an assessment)

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a range of mental health services, including psychiatric assessment and treatment, psychological and neuropsychological testing, and individual, family and group therapy.

Featured Articles

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider LifeStance Health Group, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and LifeStance Health Group wasn’t on the list.

Although LifeStance Health Group currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

[ad_2]

Trending